

Table 3 Effect measures in trials with significant changes.

Proces measures (PM) (No. of trials in which PM was included)	Author	Effect
Foot examination (5)	Kiefe Glasgow Frijling	OR 1,33; 95%CI 1,05-1,69 RR 4,38; 95%CI 2,42-7,91; boc OR 1,68; 95%CI 1,19-2,39
HbA1c measurement (2)	Kiefe	OR 1,33; 95%CI 1,04-1,69
Eye examination (5)	Frijling Glasgow	OR 1,52; 95%CI 1,07-2,16. RR 1,79; 95%CI 1,20-2,68; boc
Influenza vaccination (3)	Kiefe	OR 1,57; 95%CI 1,26-1,96
Cholesterol measurement (6)	Loback Sequist*	duc, significant positive changes reported in text HR 1,41; 95%CI 1,15-1,72
Blood glucose measurement (6)	Kenealy	Pt reminders OR 1,72; 95%CI 1,21-2,43, .. Computer reminders OR 2,55; 95%CI 1,68-3,88 Both reminders OR 1,69; 95%CI 1,11-2,59
Dietary advice (1)	Glasgow	p<0,001;duc
Micro albumin measurement (3)	Loback Glasgow	duc, significant positive changes reported in text RR 3,97; 95%CI 2,22-7,10; boc
Outcome measures (OM) (No. of trials in which OM was included)		
Level of blood pressure (3)	De fine Olivarius Hetlevik* Phillips	Δ -5 mmHg; 95%CI -7,6 to -2,4 Δ -2,3 mmHg; 95%CI -3,8 to -0,8 OR 1,19; 95%CI 1,07-1,32
Level of HbA1c. (3)	Phillips De fine Olivarius	OR 1,18; 95%CI 1,03-1,34 Δ -0,056%; 95%CI -0,081% to -0,031%
Level of cholesterol . (3)	De fine Olivarius	Δ -0,15 mmol/l; 95%CI -0,29 to -0,02
Aggregated measures (AM) (No. of trials in which AM was included)		
Odds of receiving recommended care (1)	Sequist*	OR 1,30; 95%CI 1,01-1,67
Compliance rate (1)	Loback	32% vs. 15,6 % (p=0,02*), duc
Number of recommended lab assays (1)	Glasgow	F=9,90, p<0,001; duc
Patient Satisfaction (1)	Glasgow	F=25,2, p<0,001;duc

boc=Based on own calculations on data extracted from paper

duc=Data unavailable for further calculations

OR=Odds ratio

HR=Hazard ratio

RR=Relative risk

*=Electronic feedback